Synergistic effects of tandospirone and selective serotonin reuptake inhibitors on the contextual conditioned fear stress response in rats

European Neuropsychopharmacology

Volumn 17, Issue 10, 2007, Pages 643-650

  Nishikawa, Hiroyuki ^a   Inoue, Takeshi ^a   Izumi, Takeshi ^a   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT1A receptor agonist; ; Anxiety; Conditioned fear; ; Freezing; ; Selective serotonin reuptake inhibitor (SSRI); ; Tandospirone;

Indexed keywords

CITALOPRAM; CYTOCHROME P450 3A4; DRUG METABOLITE; DRUG VEHICLE; FLUVOXAMINE; KETOCONAZOLE; PAROXETINE; SEROTONIN 1A AGONIST; SEROTONIN UPTAKE INHIBITOR; TANDOSPIRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENTIATION; FEAR; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STRESS; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEAR; ISOINDOLES; MALE; MOTOR ACTIVITY; PIPERAZINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 34547947213     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.02.010     Document Type: Article

References (42)

1. Appelberg B.G., Syvalahti E.K., Koskinen T.E., Mehtonen O.P., Muhonen T.T., and Naukkarinen H.H. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J. Clin. Psychiatry 62 (2001) 448-452
2. Borsini F., Podhorna J., and Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants?. Psychopharmacology (Berl.) 163 (2002) 121-141
3. Dimitriou E.C., and Dimitriou C.E. Buspirone augmentation of antidepressant therapy. J. Clin. Psychopharmacol. 18 (1998) 465-469
4. Erikkson E., and Humble M. Serotonin in psychiatric pathophysiology: a review of data from experimental and clinical research. In: Pohl R., and Gershon S. (Eds). The Biological Basis of Psychiatric Treatment. Prog. Basic Clin. Pharmacol. vol. 3 (1990), Karger, Basel 66-119
5. Evans S.M., Troisi II J.R., and Griffiths R.R. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J. Pharmacol. Exp. Ther. 271 (1994) 683-694
6. Fanselow M.S. Conditioned and unconditional components of post-shock freezing. Pavlov. J. Biol. Sci. 15 (1980) 177-182
7. Faravelli C., Paterniti S., and Scarpato A. 5-year prospective, naturalistic follow-up study of panic disorder. Compr. Psychiatry 36 (1995) 271-277
8. Fava M., and Davidson K.G. Definition and epidemiology of treatment-resistant depression. Psychiatr. Clin. North Am. 19 (1996) 179-200
9. Feighner J.P., and Boyer W.F. Serotonin-1A anxiolytics: an overview. Psychopathology 22 Suppl. 1 (1989) 21-26
10. Feighner J.P., Merideth C.H., and Hendrickson G.A. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J. Clin. Psychiatry 43 (1982) 103-108
11. Fischer P., Tauscher J., Kufferle B., and Kasper S. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. Int. Clin. Psychopharmacol. 13 (1998) 83-86
12. Fleishaker J.C., and Hulst L.K. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur. J. Clin. Pharmacol. 46 (1994) 35-39
13. Hashimoto S., Inoue T., and Koyama T. Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Psychopharmacology (Berl.) 123 (1996) 182-186
14. Hashimoto S., Inoue T., and Koyama T. Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats. Eur. J. Pharmacol. 378 (1999) 23-30
15. Inoue T., Koyama T., and Yamashita I. Effect of conditioned fear stress on serotonin metabolism in the rat brain. Pharmacol. Biochem. Behav. 44 (1993) 371-374
16. Inoue T., Tsuchiya K., and Koyama T. Regional changes in dopamine and serotonin activation with various intensity of physical and psychological stress in the rat brain. Pharmacol. Biochem. Behav. 49 (1994) 911-920
17. Inoue T., Tsuchiya K., and Koyama T. Serotonergic activation reduces defensive freezing in the conditioned fear paradigm. Pharmacol. Biochem. Behav. 53 (1996) 825-831
18. Inoue T., Li X.B., Abekawa T., Kitaichi Y., Izumi T., Nakagawa S., and Koyama T. Selective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdala. Eur. J. Pharmacol. 497 (2004) 311-316
19. Jacobson A.F., Dominguez R.A., Goldstein B.J., and Steinbook R.M. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy 5 (1985) 290-296
20. Joffe R.T., and Schuller D.R. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J. Clin. Psychiatry 54 (1993) 269-271
21. Kataoka Y., Shibata K., Miyazaki A., Inoue Y., Tominaga K., Koizumi S., Ueki S., and Niwa M. Involvement of the dorsal hippocampus in mediation of the antianxiety action of tandospirone, a 5-hydroxytryptamine1A agonistic anxiolytic. Neuropharmacology 30 (1991) 475-480
22. Kim J.J., and Fanselow M.S. Modality-specific retrograde amnesia of fear. Science 256 (1992) 675-677
23. Koo J.W., Han J.S., and Kim J.J. Selective neurotoxic lesions of basolateral and central nuclei of the amygdala produce differential effects on fear conditioning. J. Neurosci. 24 (2004) 7654-7662
24. Lam Y.W., Alfaro C.L., Ereshefsky L., and Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J. Clin. Pharmacol. 43 (2003) 1274-1282
25. Landen M., Eriksson E., Agren H., and Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 19 (1999) 268-271
26. LeDoux J.E. The amygdala and emotions: a view through fear. In: Aggleton J.P. (Ed). The Amygdala: A Functional Analysis. 2nd ed. (2000), Oxford Univ. Press, Oxford 289-310
27. Li X.B., Inoue T., Hashimoto S., and Koyama T. Effect of chronic administration of flesinoxan and fluvoxamine on freezing behavior induced by conditioned fear. Eur. J. Pharmacol. 425 (2001) 43-50
28. Li X.B., Inoue T., Abekawa T., Weng S., Nakagawa S., Izumi T., and Koyama T. 5-HT(1A) receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT(1A) receptors in the hippocampus and amygdala. Eur. J. Pharmacol. 532 (2006) 74-80
29. Nishitsuji K., To H., Murakami Y., Kodama K., Kobayashi D., Yamada T., Kubo C., and Mine K. Tandospirone in the treatment of generalized anxiety disorder and mixed anxiety-depression. Clin. Drug Invest. 24 (2004) 121-126
30. Nishitsuji K., To H., Shimizu T., Yanase Y., Yamada T., Hara C., Mine K., and Higuchi S. The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress. Eur. Neuropsychopharmacol. 16 (2006) 376-382
31. Niwa T., Shiraga T., Ishii I., Kagayama A., and Takagi A. Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol. Pharm. Bull. 28 (2005) 1711-1716
32. Nutt D.J. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 10 (2005) 49-56
33. Ohmori T., Abekawa T., Muraki A., and Koyama T. Competitive and noncompetitive NMDA antagonists block sensitization to methamphetamine. Pharmacol. Biochem. Behav. 48 (1994) 587-591
34. Phelps E.A., and LeDoux J.E. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 48 (2005) 175-187
35. Redrobe J.P., and Bourin M. Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psychopharmacology (Berl.) 138 (1998) 198-206
36. Sacchetti B., Lorenzini C.A., Baldi E., Tassoni G., and Bucherelli C. Auditory thalamus, dorsal hippocampus, basolateral amygdala, and perirhinal cortex role in the consolidation of conditioned freezing to context and to acoustic conditioned stimulus in the rat. J. Neurosci. 19 (1999) 9570-9578
37. Sanders M.J., Wiltgen B.J., and Fanselow M.S. The place of the hippocampus in fear conditioning. Eur. J. Pharmacol. 463 (2003) 217-223
38. Stocchi F., Nordera G., Jokinen R.H., Lepola U.M., Hewett K., Bryson H., and Iyengar M.K. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry 64 (2003) 250-258
39. Suzuki M., Uchiumi M., and Murasaki M. Effects of tandospirone, a 5-HT1A receptor-related anxiolytic, on daytime sleepiness and psychomotor functions: a comparative double-blind study with diazepam. Yakubutsu, Seishin, Kodo 13 (1993) 213-224
40. Van Ameringen M., Mancini C., and Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J. Affect. Disord. 39 (1996) 115-121
41. Yamada K., Yagi G., and Kanba S. Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial. Psychiatry Clin. Neurosci. 57 (2003) 183-187
42. Zohar J., and Westenberg H.G. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr. Scand., Suppl. 403 (2000) 39-49